Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Nkarta, Inc.

NKTX ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.56

▼ -6.02%

Market Cap $111.73M · Vol 262.80K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$111.73M

Micro Cap

Div Yield

N/A

EPS Growth

-25.90%

YoY

RSI (14)

14.12

Momentum

Beta

1.19

vs Market

52W High

$3.72

58.01% below

52W Low

$1.54

1.30% above

Volume

262.80K

Avg 210.55K

P/B

0.42

Price-to-book

ROE

N/A

Return on equity

Free Float

94.95%

Public shares

Shariah Compliance8 STANDARDS

✗ Nkarta, Inc. (NKTX) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NKTX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-12.85%

-40.46%

-27.44%

-43.68%

YTD

-15.68%

-25.00%

-23.15%

-90.05%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-104,084,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-22.99% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.42
P/FCF	N/A
EPS Growth	-25.90%
Outstanding Shares	71.62M

Technical Indicators

50-Day SMA	$2.44
200-Day SMA	$2.53
RSI (14)	14.12
Beta	1.19
52-Week High	$3.72
52-Week Low	$1.54

Volume Today	262.80K
Avg Daily Volume (30D)	210.55K
Relative Volume	1.25x
Volatility (10D)	52.02
Volatility (30D)	50.81
Free Float	94.95%

Analyst Consensus

BUY

Current Price $1.56

Mean Target $10.83

52W Low$1.54 52W High$3.72

Current

Target

$1.54 $3.72

Current Analyst target

+594.44% upside potential · 6 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00JXHS9H6

ISINUS65487U1088

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -2.98% ARGX.BR argenx SE +0.35% ARGX argenx SE -0.55% GMAB.CO Genmab A/S +3.27% GMAB Genmab A/S +1.01%

Company Profile

Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.